The next major explosion is going to be when genetics and computers come together. I’m talking about an organic computer — about biological substances that can function like a semiconductor. — Alvin Toffler
Progress in genetic approaches are transforming many areas of medicine, including psychiatry. While the genetics of schizophrenia have been most actively studied, Major Depressive Disorder (MDD) is a debilitating condition which affects millions of people worldwide, causing a massive toll of human suffering and economic loss, according to the World Health Organization. As with psychiatric conditions in general, the biology of MDD is worked out to a limited extent only, though that is changing. Adding the deep layer of genetic analysis to understanding the causes of MDD, identifying what genes are affected, and what they actually do, will advance the prevention, diagnosis and treatment of MDD, while also generally expanding our grasp of how the brain works to give rise to our everyday experiences in wellness and infirmity.
Since MDD can present in so many different ways, ranging from being clinically mild and short-lasting, to recurring over and over again, to being highly chronic and treatment-resistant, it is important to understand the genetics in order to figure out what is going on and what can be done. It’s highly complex, so the ultimate goal is having a systemic understanding. How do genetic factors come together both early on in development, and across the lifespan, to interact with brain development, epigenetic effects, and social and environmental factors to give rise to what we call depression?
Where are the depression genes?
In a landmark paper on the genetics of Major Depression, published in Nature Genetics (2018), a large consortium of researchers analyzed genetic data from 135,458 people with MDD, compared with 344,901 healthy controls. This genetic data, derived from a variety of sources including prior research databases and commercial sources such as 23andMe, was analyzed using a variety of sophisticated statistical approaches.
These findings were cross-referenced against existing research on gene function as related to a variety of important factors such as brain development, sleep-related genes, genes for stress response, and so on, to clarify the role of MDD genetics in understanding symptoms and implications for treatment and future research. Multiple genetic changes work together to increase the odds of having different forms of depression, in the face of environmental factors. As depression may range from transient and mild, to chronic and debilitating, we expect that depression will have many different sets of genetic alterations, depending on the clinical picture. Until this study, research only had identified 14 loci associated with specific genes connected with depression, and sometimes other conditions.
By looking at patterns in over 9 million single gene mutations (single nucleotide polymorphisms or SNPs — “snips”), the research group identified 44 statistically-significant genetic spots (“loci”) involved with MDD. SNPs themselves don’t mean anything in terms of genetic function, but are variations in DNA patterns which can be analyzed to map out genetic hotspots for given conditions. There are 44 loci identified in this study independently associated with elevated risk for MDD. But what do the genes near these loci do, and how does this affect whether or not someone becomes clinically depressed?
Some genes are associated with weight and body size (OLFM4 and NEGR1), others with neuron development and brain inflammation (LRFN5), and regulation of genes governing over-activation in the fight-flight systems (RBFOX1). Another group of 153 genes are associated largely with proteins which tell the immune system which cells are friendly, and which are not (major histocompatibility complex MHC proteins), and still other genes are connected with cell signaling, affecting neurotransmitter systems for dopamine (DRD2) and a target for some current medications, calcium signaling (CACNA1E and CACNA2D1), the excitatory neurotransmitter glutamate (GRIK5 and GRM5), and genes associated with presynaptic vesicle trafficking (PCLO), essentially the neuron’s postal service for delivering critical messages to the next neuron down the line. They also found overlap with 6 genes identified in schizophrenia studies, some MHC genes, and related to brain development (TCF4). Clearly, it truly is a complex picture. And it only gets even more complicated.
The functions of genes
The study authors go on to discuss what some of these genetic findings may mean, when interpreted in light of information about clinical function, neuroscience, and other existing areas of scholarship. For instance, functional genes implicated in this study may related to brain activity in the prefrontal and anterior cingulate cortex areas of the brain, areas involved with executive functions, emotion regulation, and decision-making. The data also suggests that such genes are more likely affecting neurons, rather than other important supportive cell types in the brain. Other gene types are found in broad groups of mammals, and not just human beings or apes, and related to gene regulation, how genes are read and translated to be either more active or less active depending on outside influences in terms of how chromosomes are either open and available to be read, or coiled up and packed away. Other genes implicated in depression guide a process called DNA methylation. Among other important functions, DNA methylation is a key mechanism governing epigenetic effects, in which parents pass adaptations to stress on to the next generations by increasing or decreasing gene activity without changing the underlying DNA sequence.
Further gene groups connected with synaptic functions (the synapse is where neurons connect with one another), the shapes that neurons can grow into (neuronal morphogenesis), and a variety of genes involved with other aspects of cell development, cell communication, inflammation and immune response, and notably genes governing sleep and wakefulness, thought to be critical in most forms of depression. As all of these genes are read into actual functional proteins throughout the brain, know where they are and what they do present opportunities for clinical intervention. At the same time, none of these genes is really specific for depression. As depression comes in many shapes and sizes, and overlaps with many other medical and psychiatric conditions, it isn’t surprising that depression genes also were found to overlap with additional conditions, not just schizophrenia but anxiety disorders and others.
Such interventions can be in the form of medications which interact with those proteins, or compensate for abnormal activity, and genetic therapies to alter or replace faulty genes. Understanding how specific functions, such as inflammation, are dysregulated at the genetic level allows for a better understanding of how different kinds of depression happen, and what can be done to alleviate issues associated with that function in a very targeted way. To illustrate, not all treatments which reduce inflammation would improve depression, but understanding which genes increase the risk for depression may identify ways to modify specific inflammation pathways which will reduce depression symptoms.
As with other medical conditions, understanding the genetics of depression opens up doors for diagnosis, prevention and treatment. As the genetic database expands, and research techniques similar to those in the current study are used to look at other conditions including anxiety disorder and ADHD. Pharmacogenomics for example, now in regular clinical use, allows us to make more informed medication choices based on individual genetic analysis, saving time and reducing the risk of adverse reactions (“side effects”) compared with medication selection based solely on clinical experience and trial-and-error.
As disease models continue to be developed and refined, clinical tools based on genetic and environmental analysis will allow for more accurate diagnosis of depression and better treatment, the ultimate in personalized medicine. It will become possible via genetic and other information, to identify early on who is at risk for developing depression, and take preventive steps, providing environmental and potentially medical interventions, or even individualized genetic therapies, to keep depression from happening in the first place. Ethical questions notwithstanding, as with other inherited traits, it may be possible to select embryos with lower genetic risk for mental illness, or even modify genes around the time of conception to achieve desired outcomes.
Originally published at www.psychologytoday.com.